EUVIMEDEUVIMED entdecken
Crossref

Targeting glycogen synthase kinase-3β in pancreatic ductal adenocarcinoma: Mechanisms and clinical translation

Zi-Ke Zhang, Sen-Bang Yao, Hao Sun, Chao Wang, Hao-Jun Huang

World Journal of Gastrointestinal Oncology · 04.11.2026

DOI: 10.4251/wjgo.124979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 04.11.2026. Verfasst von Zi-Ke Zhang und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting glycogen synthase kinase-3β (GSK-3β), encoded by GSK3B, offers a strategy for disrupting pancreatic ductal adenocarcinoma (PDAC) survival and treatment adaptation.Experimental studies, including genetic perturbation and patient-derived models, have connected this kinase to replication-stress tolerance, protein turnover, and epithelial plasticity.In experimental PDAC, GSK-3β inhibition can enhance chemotherapy activity through effects on survival transcription and checkpoint signaling; opposing β-catenin and PTEN responses make treatment sensitivity dependent on substrate and cellular context.This review examines the direct PDAC mechanisms, evaluates elraglusib development, and relates drug specificity and candidate biomarkers to patient selection.A randomized phase II trial in previously untreated metastatic PDAC reported longer overall survival with elraglusib plus gemcitabine/nab-paclitaxel, alongside a nonsignificant progression-free-survival difference and greater toxicity.Clinical translation faces three related challenges: Confirming benefit at tolerable chemotherapy exposure, distinguishing kinase inhibition from elraglusib's additional microtubule activity, and identifying treatment-predictive tumor dependencies.Integrating tumor pharmacodynamics with functional models and randomized clinical outcomes could establish when GSK-3β-directed treatment adds value in PDAC and guide the development of rational combinations.

Zitieren

APA

Zhang, Z., Yao, S., Sun, H., Wang, C., & Huang, H. (2026). Targeting glycogen synthase kinase-3β in pancreatic ductal adenocarcinoma: Mechanisms and clinical translation. World Journal of Gastrointestinal Oncology. https://doi.org/10.4251/wjgo.124979

Vancouver

Zhang Z, Yao S, Sun H, Wang C, Huang H. Targeting glycogen synthase kinase-3β in pancreatic ductal adenocarcinoma: Mechanisms and clinical translation. World Journal of Gastrointestinal Oncology. 2026. doi:10.4251/wjgo.124979

BibTeX
@article{Zhang2026,
  author = {Zhang, Zi-Ke and Yao, Sen-Bang and Sun, Hao and Wang, Chao and Huang, Hao-Jun},
  title = {Targeting glycogen synthase kinase-3β in pancreatic ductal adenocarcinoma: Mechanisms and clinical translation},
  journal = {World Journal of Gastrointestinal Oncology},
  year = {2026},
  doi = {10.4251/wjgo.124979}
}
Kostenlos starten →